Erdosteine: Mechanism of Action, Indications and Important Notes

Erdosteine is an active substance from the group of mucolytics (mucus-thinning agents) used in respiratory conditions where viscous mucus obstructs the airways and makes expectoration difficult. The active substance belongs to the group of thiol-containing mucolytics and is characterised by a combination of mucus-thinning and antioxidant properties. Erdosteine is used in acute and chronic respiratory conditions associated with excessive and viscous mucus production.

Conditions such as chronic obstructive pulmonary disease (COPD), chronic bronchitis and acute exacerbations of bacterial respiratory infections are frequently accompanied by impaired mucociliary clearance. The cilia of the bronchial mucosa are restricted in their cleaning function, and mucus becomes more viscous than normal. Mucolytics such as erdosteine can improve the flow properties of secretions in these situations and make expectoration easier.

Mechanism of Action

Erdosteine is a prodrug: after oral administration, it is converted in the liver to active metabolites that exert the actual effect. These active metabolites contain free thiol groups, which are responsible for several mechanisms of action.

Mucolytic Effect

The thiol groups of the active erdosteine metabolites can cleave disulphide bonds in mucins. Mucins are high-molecular-weight glycoproteins that form mucus and are responsible for its viscosity. Cleaving these disulphide bonds shortens the long mucin polymer chains, making mucus less viscous. It can then be more easily transported by the ciliated epithelium of the bronchi and expectorated.

Antioxidant Effect

Erdosteine shows antioxidant properties that go beyond its purely mucolytic effect. The free thiol groups can scavenge reactive oxygen species (oxidative stress). In respiratory diseases, particularly in COPD and in smokers, oxidative stress is a significant factor contributing to inflammation and tissue damage. By scavenging free radicals, erdosteine may exert a protective effect on the bronchial epithelium.

Inhibition of Bacterial Adhesion

Some investigations suggest that erdosteine can reduce the adhesion of bacteria to the bronchial epithelium. This effect could play a role in the prevention and treatment of bacterial respiratory infections, although the clinical significance of this mechanism is still being researched.

Improvement of Ciliary Activity

Erdosteine can also positively influence the activity of cilia in the bronchial epithelium. Improved ciliary activity supports the natural self-cleaning mechanism of the airways, as mucus transport towards the pharynx occurs more effectively.

Indications

Acute Bronchitis and Acute Exacerbations of COPD

In acute respiratory infections such as acute bronchitis with productive cough and viscous mucus, erdosteine can be used as a mucus-thinning agent to facilitate expectoration and shorten the duration of symptoms. Clinical studies show that erdosteine can reduce symptom burden in acute exacerbations of COPD. This relates to both the volume of mucus and its viscosity, and thus overall to cough.

Chronic Bronchitis and COPD

In chronic bronchitis and COPD, characterised by persistent mucus-producing cough and reduced mucus clearance, erdosteine can also be used as long-term therapy. Studies suggest that mucolytics can reduce exacerbation rates in COPD patients. Erdosteine is approved in some European countries as a mucolytic in COPD and chronic bronchitis.

Dosage Forms and Dosing

Erdosteine is available as hard capsules and as granules for preparation of a suspension. The typical dose for adults is 300 mg three times daily or 600 mg twice daily, depending on the preparation and medical recommendation. Duration of therapy depends on the clinical picture: generally up to ten days for acute conditions, and longer for chronic conditions under medical supervision. A dose adjustment may be required in cases of impaired renal or hepatic function.

Important Notes

Erdosteine achieves its best effect when adequate fluid intake is maintained. Good hydration supports the mucolytic effect, as more fluid mucus can be more easily transported and expectorated. Erdosteine can be taken with or independently of meals.

In respiratory conditions with an underlying bacterial infection requiring antibiotic therapy, erdosteine is not a substitute for antibiotics, but can be used in addition to improve mucus clearance and alleviate symptoms. The decision on antibiotic therapy is made by the treating physician.

Mucolytics should be used for productive, mucus-laden cough. In dry irritative cough without mucus production, their use is not appropriate. Medical diagnosis before therapy is recommended to clarify the cause of the cough.

Adverse Effects

Erdosteine is generally well tolerated. Possible adverse effects include:

• Gastrointestinal complaints such as nausea, gastric irritation and abdominal pain, especially at the start of therapy
• Diarrhoea in individual cases
• Headache, rarely
• Allergic reactions to the active substance are rare but possible
• A characteristic sulphurous odour of the urine may occur, as erdosteine metabolites contain thiol groups; this is harmless

Drug Interactions

No clinically significant interactions of erdosteine with other medicines are known that would require dose adjustment. However, since erdosteine can influence the adhesion of bacteria to mucosae and alter the mucus layer, it should be noted when taking antibiotics simultaneously that erdosteine may improve the penetration of antibiotics into bronchial secretions. This is pharmacologically a desired synergistic effect. Medical advice is generally important with polypharmacy.

Erdosteine on Sanoliste

On Sanoliste you will find general practitioners, internists and pulmonologists who offer competent diagnostics and therapy for respiratory conditions such as chronic bronchitis, COPD and acute lower respiratory tract infections. Chronic respiratory conditions such as COPD require long-term, specialist-supervised treatment that can include, in addition to pharmacological measures, smoking cessation, respiratory physiotherapy and, if necessary, oxygen therapy.

The content on this page is for general information purposes only. It does not replace advice from a physician. In Germany, erdosteine is available on prescription or without prescription depending on the preparation and indication; medical advice is recommended.

Frequently Asked Questions about Erdosteine

How does erdosteine differ from acetylcysteine?

Both active substances belong to the group of thiol-containing mucolytics and share the mechanism of disulphide bond cleavage in mucins. Acetylcysteine (ACC) is directly active as a free thiol and does not need to be activated in the liver first. Erdosteine, on the other hand, is a prodrug and is converted to active metabolites after oral administration. This prodrug property can improve gastric tolerability, as the free thiol groups are only released after absorption. Erdosteine shows in some studies also specific effects on ciliary activity and bacterial adhesion that are not described for acetylcysteine in this form. Which active substance is more suitable in an individual case is decided by the treating physician.

Can erdosteine be used in children?

Erdosteine is approved in Germany for adults. Use in children is age-dependent and follows the respective product information for the preparation. Other mucolytics and secretolytics are available for children that are approved for paediatric patients and adapted to appropriate doses. Medical advice is absolutely required before use in children.

Does erdosteine also help with cold-related cough?

Erdosteine is effective for productive cough with viscous mucus, such as can occur in acute bronchitis or exacerbated chronic respiratory conditions. In the case of dry irritative cough, as frequently occurs at the start of a viral cold, the effect of a mucolytic such as erdosteine is not to be expected, as there is no viscous secretion to be dissolved. In such cases, other therapeutic approaches may be more appropriate. Medical assessment helps to choose the correct therapeutic approach.